Literature DB >> 15695477

Patient perspectives: Tijuana cancer clinics in the post-NAFTA era.

Ralph W Moss1.   

Abstract

This article contains observations and historical considerations on cancer and complementary and alternative medicine (CAM) in the Tijuana, Mexico, area. There are approximately 2 dozen such clinics in Tijuana, some of which have been treating international cancer patients since 1963. Among the first clinics to be established were the Bio-Medical Center (Hoxsey therapy), Oasis of Hope (a Laetrile-oriented clinic), and a series of clinics affiliated with the Gerson diet therapy. These original clinics were established mainly by American citizens in response to increased regulation of nonstandard therapies in the United States, particularly after passage of the Kefauver-Harris Amendments to the Food, Drug and Cosmetics Act in 1962. In the 1970s, the Tijuana clinics proliferated with the upsurge of interest in Laetrile (amygdalin). By 1978, 70,000 US cancer patients had taken Laetrile for cancer treatment, and many of those had gone to Tijuana to receive it. The popularity of the Tijuana clinics peaked in the mid-1980s. Although many new clinics opened after then, a dozen have folded in the past 10 years alone. The turning point for the clinics came with passage of the North American Free Trade Agreement (NAFTA), which facilitated greater cooperation among the antifraud authorities of Canada, the United States, and Mexico. In 1994, the tripartite members of NAFTA formed the Mexico-United States-Canada Health Fraud Work Group, or MUCH, whose brief is to strengthen the 3 countries' ability to prevent cross-border health fraud. Under the auspices of MUCH and its members, regulatory crackdowns began in earnest early in 2001. The clinics were also badly affected by the general downturn in travel after 9/11. If these trends continue, many Tijuana clinics are unlikely to survive. Some suggestions are made for how the Tijuana clinics could be reorganized and reformed to minimize the likelihood of governmental actions and to maximize public support. Such reforms center on 5 main areas: (1) research, (2) physical plant, (3) finances, (4) ethics, and (5) education.

Entities:  

Mesh:

Year:  2005        PMID: 15695477     DOI: 10.1177/1534735404273918

Source DB:  PubMed          Journal:  Integr Cancer Ther        ISSN: 1534-7354            Impact factor:   3.279


  6 in total

1.  Stem-cell tourism and scientific responsibility. Stem-cell researchers are in a unique position to curb the problem of stem-cell tourism.

Authors:  Zubin Master; David B Resnik
Journal:  EMBO Rep       Date:  2011-09-30       Impact factor: 8.807

2.  The anti-cancer effect of amygdalin on human cancer cell lines.

Authors:  Asghar Arshi; Sayed Mostafa Hosseini; Fataneh Saleh Khaje Hosseini; Zahra Yousefnejad Amiri; Fatemeh Sadat Hosseini; Mahsa Sheikholia Lavasani; Hossein Kerdarian; Maryam Safarpour Dehkordi
Journal:  Mol Biol Rep       Date:  2019-02-05       Impact factor: 2.316

3.  Amygdalin blocks bladder cancer cell growth in vitro by diminishing cyclin A and cdk2.

Authors:  Jasmina Makarević; Jochen Rutz; Eva Juengel; Silke Kaulfuss; Michael Reiter; Igor Tsaur; Georg Bartsch; Axel Haferkamp; Roman A Blaheta
Journal:  PLoS One       Date:  2014-08-19       Impact factor: 3.240

4.  Amygdalin influences bladder cancer cell adhesion and invasion in vitro.

Authors:  Jasmina Makarević; Jochen Rutz; Eva Juengel; Silke Kaulfuss; Igor Tsaur; Karen Nelson; Jesco Pfitzenmaier; Axel Haferkamp; Roman A Blaheta
Journal:  PLoS One       Date:  2014-10-15       Impact factor: 3.240

5.  Amygdalin promotes the activity of T cells to suppress the progression of HBV-related hepatocellular carcinoma via the JAK2/STAT3 signaling pathway.

Authors:  Ruoyu Wang; Dong Zhang; Kewei Sun; Jianping Peng; Wenfang Zhu; Sihan Yin; Dan Tang; Yunan Wu
Journal:  BMC Infect Dis       Date:  2021-01-12       Impact factor: 3.090

Review 6.  Amygdalin: Toxicity, Anticancer Activity and Analytical Procedures for Its Determination in Plant Seeds.

Authors:  Ewa Jaszczak-Wilke; Żaneta Polkowska; Marek Koprowski; Krzysztof Owsianik; Alyson E Mitchell; Piotr Bałczewski
Journal:  Molecules       Date:  2021-04-13       Impact factor: 4.411

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.